<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZENIQUIN- marbofloxacin tablet </strong><br>Zoetis Inc.<br></p></div>
<h1>Zeniquin<span class="Sup">®</span><br> (marbofloxacin)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Tablets</span></p>
<p><span class="Italics">For oral use in dogs and cats only</span></p>
<p><span class="Bold">CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.</span></p>
<p><span class="Bold">Federal law prohibits the extralabel use of this drug in food-producing animals.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">DESCRIPTION:</span> Marbofloxacin is a synthetic broad-spectrum antibacterial agent from the fluoroquinolone class of chemotherapeutic agents. Marbofloxacin is the non-proprietary designation for 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2] benzoxadiazine-6-carboxylic acid. The empirical formula is C<span class="Sub">17</span>H<span class="Sub">19</span>FN<span class="Sub">4</span>O<span class="Sub">4</span> and the molecular weight is 362.36. The compound is soluble in water; however, solubility decreases in alkaline conditions. The N-octanol/water partition coefficient (Kow) is 0.835 measured at pH 7 and 25°C.</p>
<p><span class="Bold">Figure 1: </span>Chemical structure of marbofloxacin</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5&amp;name=zeniquin-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<p class="First"><span class="Bold">CLINICAL PHARMACOLOGY:</span> Marbofloxacin is rapidly and almost completely absorbed from the gastrointestinal tract following oral administration to fasted animals. Divalent cations are generally known to diminish the absorption of fluoroquinolones. The effects of concomitant feeding on the absorption of marbofloxacin have not been determined. (See<span class="Bold"><a href="#DI"> Drug Interactions</a>.</span>) In the dog, approximately 40% of an oral dose of marbofloxacin is excreted unchanged in the urine<span class="Sup">1</span>. Excretion in the feces, also as unchanged drug, is the other major route of elimination in dogs. Ten to 15% of marbofloxacin is metabolized by the liver in dogs.</p>
<p><span class="Italics">In vitro </span>plasma protein binding of marbofloxacin in dogs was 9.1% and in cats was 7.3%. In the cat, approximately 70% of an oral dose is excreted in the urine as marbofloxacin and metabolites with approximately 85% of the excreted material as unchanged drug. Pharmacokinetic parameters related to intravenous dosing were estimated in a study of 6 healthy adult beagle dogs, and are summarized in Table 1. The absolute bioavailability following dosing of oral tablets to the same animals was 94%.</p>
<p>Marbofloxacin plasma concentrations were determined over time in healthy adult beagle dogs (6 dogs per dosage group) following single oral doses of 1.25 mg/lb or 2.5 mg/lb. Absorption of orally administered marbofloxacin increases proportionally over the dose range of 1.25 to 2.5 mg/lb. Marbofloxacin plasma concentrations were determined over time in 7 healthy adult male cats following a single oral dose of 2.5 mg/lb. Plasma pharmacokinetic parameters following oral dosing of dogs and cats are summarized in Figures 2 and 3 and in Table 2. Based on the terminal elimination half-life and the dosing interval, steady-state levels are reached after the third dose and are expected to be approximately 25% greater in dogs and 35% greater in cats than those achieved after a single dose. Marbofloxacin is widely distributed in canine tissues. Tissue concentrations of marbofloxacin were determined in healthy male beagle dogs (4 dogs per time period) at 2, 18 and 24 hours after a single oral dose (1.25 or 2.5 mg/lb) and are summarized in Tables 3a and 3b.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Mean pharmacokinetic parameters following intravenous administration of marbofloxacin to 6 adult beagle dogs at a dosage of 2.5 mg/lb.</span></caption>
<col align="left" valign="top" width="70%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th align="left" valign="bottom">Parameter</th>
<th align="center">Estimate ± SD<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>n=6</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>SD = standard deviation</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Total body clearance, (mL/h∙kg)</td>
<td align="center">94 ± 8</td>
</tr>
<tr>
<td align="left">Volume of distribution at steady state, V<span class="Sub">ss</span>, (L/kg)</td>
<td align="center">1.19 ± 0.08</td>
</tr>
<tr>
<td align="left">AUC<span class="Sub">0-inf</span> (µg∙h/mL)</td>
<td align="center">59 ± 5</td>
</tr>
<tr class="Last">
<td align="left">Terminal plasma elimination half-life, t<span class="Sub">1/2</span>(h)</td>
<td align="center">9.5 ± 0.7</td>
</tr>
</tbody>
</table>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: Mean pharmacokinetic parameters following oral administration of marbofloxacin tablets to adult beagle dogs at a nominal dosage of 1.25 mg/lb or 2.5 mg/lb and to cats at 2.5 mg/lb.<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th align="left" valign="bottom">Parameter</th>
<th align="center" valign="bottom">Dog<br>Estimate ± SD<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a><br>(1.25 mg/lb)<br>n=6</th>
<th align="center" valign="bottom">Dog<br>Estimate ± SD<a href="#footnote-3" class="Sup">†</a><br>(2.5 mg/lb)<br>n=6</th>
<th align="center" valign="bottom">Cat<br>Estimate ± SD<a href="#footnote-3" class="Sup">†</a><br>(2.5 mg/lb)<br>n=7</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>mean actual dosages administered to dogs were 1.22 mg/lb and 2.56 mg/lb, respectively, and the mean actual dosage administered to cats was 2.82 mg/lb.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>SD = standard deviation</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Time of maximum concentration, T<span class="Sub">max</span>(h)</td>
<td align="center">1.5 ± 0.3</td>
<td align="center">1.8 ± 0.3</td>
<td align="center">1.2 ± 0.6</td>
</tr>
<tr>
<td align="left">Maximum concentration, C<span class="Sub">max</span>, (µg/mL)</td>
<td align="center">2.0 ± 0.2</td>
<td align="center">4.2 ± 0.5</td>
<td align="center">4.8 ± 0.7</td>
</tr>
<tr>
<td align="left">AUC<span class="Sub">0-inf</span> (µg•h/mL)</td>
<td align="center">31.2 ± 1.6</td>
<td align="center">64 ± 8</td>
<td align="center">70 ± 6</td>
</tr>
<tr class="Last">
<td align="left">Terminal plasma elimination half-life, t<span class="Sub">1/2</span>(h)</td>
<td align="center">10.7 ± 1.6</td>
<td align="center">10.9 ± 0.6</td>
<td align="center">12.7 ± 1.1</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 2: </span>Mean plasma concentrations (µg/mL) following single oral administration of marbofloxacin to adult beagle dogs at dosages of 1.25 mg/lb or 2.5 mg/lb.</p>
<p>* See<a href="#table4"> Table 4 </a>in<span class="Bold"> Microbiology </span>section for MIC data.</p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5&amp;name=zeniquin-02.jpg"></div>
<p><span class="Bold">Figure 3: </span>Mean plasma concentrations (µg/mL) following single oral administration of marbofloxacin to adult cats at a dosage of 2.5 mg/lb.</p>
<p>* See<a href="#table5"> Table 5 </a>in<span class="Bold"> Microbiology </span>section for MIC data.</p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5&amp;name=zeniquin-03.jpg"></div>
<a name="tablea3"></a><table width="75%">
<caption><span>Table 3a: Tissue distribution following a single oral administration of marbofloxacin tablets to adult beagle dogs at a dosage of 1.25 mg/lb<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>.</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="3">Marbofloxacin Concentrations (µg/g ± SD)</th>
</tr>
<tr class="Last">
<th align="left" valign="bottom">Tissue</th>
<th align="center">2 hours<br>(n=4)</th>
<th align="center">18 hours<br>(n=4)</th>
<th align="center">24 hours<br>(n=4)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>SD = standard deviation</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">bladder</td>
<td align="center">4.8 ± 1.1</td>
<td align="center">2.6 ± 1.5</td>
<td align="center">1.11 ± 0.19</td>
</tr>
<tr>
<td align="left">bone marrow</td>
<td align="center">3.1 ± 0.5</td>
<td align="center">1.5 ± 1.5</td>
<td align="center">0.7 ± 0.2</td>
</tr>
<tr>
<td align="left">feces</td>
<td align="center">15 ± 9</td>
<td align="center">48 ± 40</td>
<td align="center">26 ± 11</td>
</tr>
<tr>
<td align="left">jejunum</td>
<td align="center">3.6 ± 0.5</td>
<td align="center">1.3 ± 1.0</td>
<td align="center">0.7 ± 0.3</td>
</tr>
<tr>
<td align="left">kidney</td>
<td align="center">7.1 ±1.7</td>
<td align="center">1.4 ± 0.5</td>
<td align="center">0.9 ± 0.3</td>
</tr>
<tr>
<td align="left">lung</td>
<td align="center">3.0 ± 0.5</td>
<td align="center">0.8 ± 0.2</td>
<td align="center">0.57 ± 0.19</td>
</tr>
<tr>
<td align="left">lymph node</td>
<td align="center">5.5 ± 1.1</td>
<td align="center">1.3 ± 0.3</td>
<td align="center">1.0 ± 0.3</td>
</tr>
<tr>
<td align="left">muscle</td>
<td align="center">4.1 ± 0.3</td>
<td align="center">1.0 ± 0.3</td>
<td align="center">0.7 ± 0.2</td>
</tr>
<tr>
<td align="left">prostate</td>
<td align="center">5.6 ± 1.4</td>
<td align="center">1.8 ± 0.6</td>
<td align="center">1.1 ± 0.4</td>
</tr>
<tr class="Last">
<td align="left">skin</td>
<td align="center">1.9 ± 0.6</td>
<td align="center">0.41 ± 0.13</td>
<td align="center">0.32 ± 0.08</td>
</tr>
</tbody>
</table>
<a name="tableb3"></a><table width="75%">
<caption><span>Table 3b: Tissue distribution following a single oral administration of marbofloxacin tablets to adult beagle dogs at a dosage of 2.5 mg/lb.</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="3">Marbofloxacin Concentrations (µg/g ± SD<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>)</th>
</tr>
<tr class="Last">
<th align="left" valign="bottom">Tissue</th>
<th align="center">2 hours<br>(n=4)</th>
<th align="center">18 hours<br>(n=4)</th>
<th align="center">24 hours<br>(n=4)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>SD = standard deviation</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">bladder</td>
<td align="center">12 ± 4</td>
<td align="center">6 ± 7</td>
<td align="center">1.8 ± 0.4</td>
</tr>
<tr>
<td align="left">bone marrow</td>
<td align="center">4.6 ± 1.5</td>
<td align="center">1.28 ± 0.13</td>
<td align="center">0.9 ± 0.3</td>
</tr>
<tr>
<td align="left">feces</td>
<td align="center">18 ± 3</td>
<td align="center">52 ± 17</td>
<td align="center">47 ± 28</td>
</tr>
<tr>
<td align="left">jejunum</td>
<td align="center">7.8 ± 1.1</td>
<td align="center">2.0 ± 0.3</td>
<td align="center">1.1 ± 0.3</td>
</tr>
<tr>
<td align="left">kidney</td>
<td align="center">12.7 ±1.7</td>
<td align="center">2.7 ± 0.3</td>
<td align="center">1.6 ± 0.2</td>
</tr>
<tr>
<td align="left">lung</td>
<td align="center">5.48 ± 0.17</td>
<td align="center">1.45 ± 0.19</td>
<td align="center">1.0 ± 0.2</td>
</tr>
<tr>
<td align="left">lymph node</td>
<td align="center">8.3 ± 0.7</td>
<td align="center">2.3 ± 0.5</td>
<td align="center">2.03 ± 0.06</td>
</tr>
<tr>
<td align="left">muscle</td>
<td align="center">7.5 ± 0.5</td>
<td align="center">1.8 ± 0.3</td>
<td align="center">1.20 ± 0.12</td>
</tr>
<tr>
<td align="left">prostate</td>
<td align="center">11 ± 3</td>
<td align="center">2.7 ± 1.0</td>
<td align="center">2.0 ± 0.5</td>
</tr>
<tr class="Last">
<td align="left">skin</td>
<td align="center">3.20 ± 0.33</td>
<td align="center">0.705 ± 0.013</td>
<td align="center">0.46 ± 0.09</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology:</span> The primary action of fluoroquinolones is to inhibit the bacterial enzyme, DNA gyrase. In susceptible organisms, fluoroquinolones are rapidly bactericidal at relatively low concentrations. Marbofloxacin is bactericidal against a broad range of gram-negative and gram-positive organisms. The <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) of pathogens isolated in clinical field studies performed in the United States were determined using National Committee for Clinical Laboratory Standards (NCCLS) standards, and are shown in Tables 4 and 5.</p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4: MIC Values<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a> (µg/mL) of marbofloxacin against pathogens isolated from skin, soft tissue and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> in dogs enrolled in clinical studies conducted during 1994–1996.</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<thead><tr class="First Last">
<th align="left" valign="bottom">Organism</th>
<th align="center">No. of Isolates</th>
<th align="center">MIC<span class="Sub">50</span>
</th>
<th align="center">MIC<span class="Sub">90</span>
</th>
<th align="center">MIC Range</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>The correlation between<span class="Italics"> in vitro </span>susceptibility data (MIC) and clinical response has not been determined.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>MIC<span class="Sub">50</span> and MIC<span class="Sub">90</span> not calculated due to insufficient number of isolates.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Italics">Staphylococcus intermedius</span></td>
<td align="center">135</td>
<td align="center">0.25</td>
<td align="center">0.25</td>
<td align="center">0.125–2</td>
</tr>
<tr>
<td align="left"><span class="Italics">Escherichia coli</span></td>
<td align="center">61</td>
<td align="center">0.03</td>
<td align="center">0.06</td>
<td align="center">0.015–2</td>
</tr>
<tr>
<td align="left"><span class="Italics">Proteus mirabilis</span></td>
<td align="center">35</td>
<td align="center">0.06</td>
<td align="center">0.125</td>
<td align="center">0.03–0.25</td>
</tr>
<tr>
<td align="left">Beta-hemolytic<span class="Italics"> Streptococcus</span><span class="Italics">, </span>(not Group A or Group B)</td>
<td align="center" valign="bottom">25</td>
<td align="center" valign="bottom">1</td>
<td align="center" valign="bottom">2</td>
<td align="center" valign="bottom">0.5–16</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Streptococcus</span>, Group D enterococcus</td>
<td align="center" valign="bottom">16</td>
<td align="center" valign="bottom">1</td>
<td align="center" valign="bottom">4</td>
<td align="center" valign="bottom">0.008–4</td>
</tr>
<tr>
<td align="left"><span class="Italics">Pasteurella multocida</span></td>
<td align="center">13</td>
<td align="center">0.015</td>
<td align="center">0.06</td>
<td align="center">≤0.008–0.5</td>
</tr>
<tr>
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="center">12</td>
<td align="center">0.25</td>
<td align="center">0.25</td>
<td align="center">0.25–0.5</td>
</tr>
<tr>
<td align="left"><span class="Italics">Enterococcus faecalis</span></td>
<td align="center">11</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">1–4</td>
</tr>
<tr>
<td align="left"><span class="Italics">Klebsiella pneumoniae</span></td>
<td align="center">11</td>
<td align="center">0.06</td>
<td align="center">0.06</td>
<td align="center">0.01–0.06</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Pseudomonas </span>spp.</td>
<td align="center">9</td>
<td align="center"><a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a></td>
<td align="center"><a href="#footnote-7" class="Sup">†</a></td>
<td align="center">0.06–1</td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">Pseudomonas aeruginosa</span></td>
<td align="center">7</td>
<td align="center"><a href="#footnote-7" class="Sup">†</a></td>
<td align="center"><a href="#footnote-7" class="Sup">†</a></td>
<td align="center">0.25–1</td>
</tr>
</tbody>
</table>
<a name="table5"></a><table width="75%">
<caption><span>Table 5: MIC Values<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a> (µg/mL) of marbofloxacin against pathogens isolated from skin and <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span> in cats enrolled in clinical studies conducted in 1995 and 1998.</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<thead><tr class="First Last">
<th align="left">Organism</th>
<th align="center">No. of Isolates</th>
<th align="center">MIC<span class="Sub">50</span>
</th>
<th align="center">MIC<span class="Sub">90</span>
</th>
<th align="center">MIC Range</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>The correlation between<span class="Italics"> in vitro </span>susceptibility data (MIC) and clinical response has not been determined.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Italics">Pasteurella multocida</span></td>
<td align="center">135</td>
<td align="center">0.03</td>
<td align="center">0.06</td>
<td align="center">≤0.008–0.25</td>
</tr>
<tr>
<td align="left">Beta-hemolytic<span class="Italics"> Streptococcus</span>
</td>
<td align="center">22</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">0.06–1</td>
</tr>
<tr>
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="center">21</td>
<td align="center">0.25</td>
<td align="center">0.5</td>
<td align="center">0.125–1</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Corynebacterium </span>spp.</td>
<td align="center">14</td>
<td align="center">0.5</td>
<td align="center">1</td>
<td align="center">0.25–2</td>
</tr>
<tr>
<td align="left"><span class="Italics">Staphylococcus intermedius</span></td>
<td align="center">11</td>
<td align="center">0.25</td>
<td align="center">0.5</td>
<td align="center">0.03–0.5</td>
</tr>
<tr>
<td align="left"><span class="Italics">Enterococcus faecalis</span></td>
<td align="center">10</td>
<td align="center">2.0</td>
<td align="center">2.0</td>
<td align="center">1.0–2.0</td>
</tr>
<tr>
<td align="left"><span class="Italics">Escherichia coli</span></td>
<td align="center">10</td>
<td align="center">0.03</td>
<td align="center">0.03</td>
<td align="center">0.015–0.03</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">Bacillus </span>spp.</td>
<td align="center">10</td>
<td align="center">0.25</td>
<td align="center">0.25</td>
<td align="center">0.125–0.25</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<p class="First"><span class="Bold">INDICATIONS AND USAGE:</span> Zeniquin (marbofloxacin) tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in dogs and cats associated with bacteria susceptible to marbofloxacin.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<p class="First"><span class="Bold">CONTRAINDICATIONS:</span> Marbofloxacin and other quinolones have been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of most species tested, the dog being particularly sensitive to this side effect. Marbofloxacin is contraindicated in immature dogs during the rapid growth phase (small and medium breeds up to 8 months of age, large breeds up to 12 months of age and giant breeds up to 18 months of age). Marbofloxacin is contraindicated in cats under 12 months of age. Marbofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<p class="First"><span class="Bold">WARNING: For use in animals only. Keep out of reach of children. </span>Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposure. Individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fluoroquinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<p class="First"><span class="Bold">PRECAUTIONS:</span> Quinolones should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>. Quinolones have been shown to produce erosions of cartilage of weight-bearing joints and other signs of <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of various species. The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. The safety of marbofloxacin in animals used for breeding purposes, pregnant, or lactating has not been demonstrated.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<p class="First"><span class="Bold">ADVERSE REACTIONS:</span> The following clinical signs were reported during the course of clinical field studies in dogs receiving marbofloxacin at dosages up to 2.5 mg/lb daily: decreased or loss of appetite (5.4%), <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span> (4.4%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2.9%). The following signs were reported in less than 1% of cases in dogs: <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span>, soft stool/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, behavioral changes, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>/<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>/<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>. One dog which had a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> the day before study enrollment experienced a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> while on marbofloxacin therapy.</p>
<p>The following clinical signs were reported during clinical field studies in cats receiving 1.25 mg/lb/day: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.1%) and soft stool (1.4%). <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> was reported in less than 1% of cases in cats.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<p class="First"><span class="Bold">DOSAGE AND ADMINISTRATION:</span> The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb.</p>
<p>For the treatment of skin and <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span>, Zeniquin tablets should be given for 2–3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, Zeniquin tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="DI"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> Compounds (e.g., sucralfate, antacids, and mineral supplements) containing divalent and trivalent cations (e.g., iron, aluminum, calcium, magnesium, and zinc) can interfere with the absorption of quinolones which may result in a decrease in product bioavailability. Therefore, the concomitant oral administration of quinolones with foods, supplements, or other preparations containing these compounds should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10"></a><p></p>
<p class="First"><span class="Bold">EFFECTIVENESS CONFIRMATION:</span> Clinical effectiveness was confirmed in bacterial skin and <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span> in dogs and cats and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (<span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>) in dogs associated with bacteria susceptible to marbofloxacin. Bacterial pathogens isolated in clinical field studies are provided in the<span class="Bold"> Microbiology </span>section.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>TARGET ANIMAL SAFETY:</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Dogs:</span> The toxicity of marbofloxacin was assessed in 12- to 14-month-old beagle dogs administered marbofloxacin at 2.5, 7.5 and 12.5 mg/lb/day for 42 days. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, reddened skin (usually involving the ears) and reddened mucous membranes were occasionally observed in all groups, including controls, but were noted most frequently in the 12.5 mg/lb group. Decreased food consumption and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> were significant in the 7.5 mg/lb and 12.5 mg/lb groups. No clinical lameness was noted in any of the treated animals. Minimal to slight lesions in the articular cartilage were observed in 1/8 placebo-treated animals and in 3/8 animals given 12.5 mg marbofloxacin/lb. Macroscopically, these lesions were <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, raised areas, or depressed, light-colored areas. Microscopically, these lesions were characterized by the presence of one or more of the following: fissuring, erosion, chondrocyte proliferation, <span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">fibrillation</span>, or vertical splitting of the articular cartilage. These cartilage lesions in treated dogs were similar to those in control dogs, and were not typical of those produced by fluoroquinolones. In addition to the above pathologic alterations, red areas of articular cartilage were noted macroscopically in 0/8 placebo-treated dogs and in 2/8 dogs from each of the three marbofloxacin-treated groups. These areas usually correlated microscopically with areas of vascularity of the articular surface, but could not be confirmed microscopically in all animals. They consisted of large blood vessels in mature fibrous connective tissue, with no indication of active vascularization due to drug-induced damage. They were considered most likely to be developmental anomalies or normal variations of the joint surface and were not considered to be related to drug treatment.</p>
<p>Marbofloxacin was administered to 12- to 14-month-old beagle dogs at a dosage of 25 mg/lb/day for 12 days. Decreased food consumption, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excessive <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, reddened skin, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span> and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> were seen in treated dogs. No clinical lameness was noted. As in the 42 day study, grossly visible, focal, red areas of articular cartilage were seen. These findings were noted in 2/6 placebo-treated dogs and in 4/6 marbofloxacintreated dogs. The foci were areas of fibrocartilage with prominent vascularization or increased vascularization of subchondral bone. Due to the appearance microscopically and macroscopically, these red foci were described as likely to be developmental anomalies or normal variations in articular cartilage.</p>
<p>Marbofloxacin administered to 3- to 4-month-old, large breed, purpose-bred mongrel dogs at a dosage of 5 mg/lb/day for 14 days resulted in marked lameness in all dogs due to articular cartilage lesions. Lameness was accompanied by <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> and activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<p class="First"><span class="Bold">Cats:</span> Marbofloxacin was administered for 42 consecutive days to 24 cats approximately 8 months old (8 cats per treatment group) at the dosages of 2.5, 7.5 and 12.5 mg/lb/day (5.5, 16.5 and 27.5 mg/kg/day). Treatment with marbofloxacin did not produce adverse effects on body weights, food consumption, serum chemistry, urinalysis or organ weight parameters. Decreased segmented neutrophil counts were observed in some cats in all treatment groups, including the placebo group, but mean counts were significantly lower in the marbofloxacin-treated groups. In some cats, absolute neutrophil counts were below normal reference values (as low as 615 <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>/μL in a marbofloxacin-treated cat and as low as 882 <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>/μL in a placebo-treated cat). Other hematological observations were not adversely affected. Clinical signs were occasionally noted in cats in the highest dosage group: excessive <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> in 4/8 cats and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of ear pinnae in 2/8 cats. Macroscopic changes in the articular cartilage of femurs were seen in one cat receiving 7.5 mg/lb and in 3 cats receiving 12.5 mg/lb. Microscopically, these gross lesions were related to a focal or multifocal <span class="product-label-link" type="condition" conceptid="439103" conceptname="Articular cartilage disorder">chondropathy</span>. Microscopic <span class="product-label-link" type="condition" conceptid="439103" conceptname="Articular cartilage disorder">chondropathy</span> not associated with macroscopic observations was also present in one cat treated with 2.5 mg/lb daily (1X the upper end of the dose range) and one additional cat treated with 7.5 mg/lb daily. There was no evidence of lameness during the course of the study. A perivascular to diffuse <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> was seen microscopically in one mid-dose cat and 4 high-dose cats. Funduscopic exam by a board-certified ophthalmologist and histologic examination of retina and optic nerve by ocular pathologists revealed no lesions in any of the treatment groups.</p>
<p>Marbofloxacin was also administered orally to 6 cats approximately 8 months of age for 14 consecutive days at a dosage of 25 mg/lb/day (55 mg/kg/day). Clinical signs associated with <span class="product-label-link" type="condition" conceptid="4240582" conceptname="Drug intolerance">drug intolerance</span> were excessive <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> in 5/6 cats and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of ear pinnae in all cats after 8 days of treatment. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> was noted occasionally in several cats and diminished activity was noted in one cat. Decreased food intake was noted in some animals, primarily males, when compared to controls. Perivascular to diffuse <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> was seen microscopically in the pinnae of all treated animals and in the standard skin samples of several animals. There was focal or multifocal articular <span class="product-label-link" type="condition" conceptid="439103" conceptname="Articular cartilage disorder">chondropathy</span> in 2/6 treated animals. One treated cat had a duodenal mucosal erosion and one treated cat had a <span class="product-label-link" type="condition" conceptid="4189591" conceptname="Pyloric ulcer">pyloric ulcer</span>. There were no observations of lameness and no adverse effects on hematology, clinical chemistry, urinalysis, or organ weight parameters. Funduscopic examination by a board-certified ophthalmologist and histologic examination of retina and optic nerve by ocular pathologists revealed no lesions.</p>
<p>A study was conducted to investigate the effect of marbofloxacin on articular cartilage of skeletally mature cats 12–14 months of age. Forty cats were randomly assigned to 4 groups of 10 cats each. Groups received placebo or marbofloxacin at dosages of 1.25, 3.75 or 7.5 mg/lb/day (2.75, 8.25 or 16.5 mg/kg/day) for 42 consecutive days. There were no treatment-related pathological changes in the joints or other tissues. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> and soft stools was noted in all treatment groups, including placebo, and increased in frequency with increasing dose and duration of treatment. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> was more apparent in the high-dose males.</p>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">STORAGE CONDITIONS:</span> Store below 30°C (86°F).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Zeniquin tablets are available in the following strengths of marbofloxacin and bottle sizes:</p>
<p>25 mg scored tablets supplied in bottles that contain 100 or 250 tablets<br>50 mg scored tablets supplied in bottles that contain 100 or 250 tablets<br>100 mg scored tablets supplied in a 50 tablet bottle<br>200 mg scored tablets supplied in a 50 tablet bottle</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-14"></a><p></p>
<h1>REFERENCES:</h1>
<p class="First">1. Schneider M,<span class="Italics"> et al: </span>Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration.<span class="Italics"> J Vet Pharmacol Therap </span>19:56–61<span class="Italics">, </span>1996.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">To report suspected adverse effects, and/or obtain a copy of the MSDS, call 1-888-963-8471.</p>
<p>NADA #141-151, Approved by FDA</p>
<p>Distributed by:<br>Zoetis Inc.<br>Kalamazoo, MI 49007</p>
<p>13910600<br> Revised: January 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 25 mg Bottle Label</h1>
<p class="First"><span class="Bold">Zeniquin<span class="Sup">®</span></span><br>(marbofloxacin)</p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Italics">For oral use in dogs and cats only</span></p>
<p><span class="Bold Italics">Antibacterial</span></p>
<p><span class="Bold">Caution: </span>Federal law restricts<br>this drug to use by or on the<br>order of a licensed veterinarian.</p>
<p><span class="Bold">Federal law prohibits the<br>extralabel use of this drug<br>in food-producing animals.</span></p>
<p><span class="Bold">25 mg</span></p>
<p><span class="Bold Italics">100 Tablets</span></p>
<p>NADA #141-151, Approved by FDA</p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 25 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5&amp;name=zeniquin-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mg Bottle Label</h1>
<p class="First"><span class="Bold">Zeniquin<span class="Sup">®</span></span><br>(marbofloxacin)</p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Italics">For oral use in dogs only</span></p>
<p><span class="Bold Italics">Antibacterial</span></p>
<p><span class="Bold">Caution: </span>Federal law restricts this drug to use<br>by or on the order of a licensed veterinarian.</p>
<p><span class="Bold">Federal law prohibits the extralabel use<br>of this drug in food-producing animals.</span></p>
<p><span class="Bold">50 mg</span></p>
<p><span class="Bold Italics">100 Tablets</span></p>
<p>NADA #141-151, Approved by FDA</p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5&amp;name=zeniquin-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label</h1>
<p class="First"><span class="Bold">Zeniquin<span class="Sup">®</span></span><br>(marbofloxacin)</p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Italics">For oral use in dogs only</span></p>
<p><span class="Bold Italics">Antibacterial</span></p>
<p><span class="Bold">Caution: </span>Federal law restricts this drug to use<br>by or on the order of a licensed veterinarian.</p>
<p><span class="Bold">Federal law prohibits the extralabel use<br>of this drug in food-producing animals.</span></p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold Italics">50 Tablets</span></p>
<p>NADA #141-151, Approved by FDA</p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5&amp;name=zeniquin-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 200 mg Bottle Label</h1>
<p class="First"><span class="Bold">Zeniquin<span class="Sup">®</span></span><br>(marbofloxacin)</p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Italics">For oral use in dogs only</span></p>
<p><span class="Bold Italics">Antibacterial</span></p>
<p><span class="Bold">Caution: </span>Federal law restricts this<br>drug to use by or on the order of a<br>licensed veterinarian.</p>
<p><span class="Bold">Federal law prohibits the<br>extralabel use of this drug<br>in food-producing animals.</span></p>
<p><span class="Bold">200 mg</span></p>
<p><span class="Bold Italics">50 Tablets</span></p>
<p>NADA #141-151, Approved by FDA</p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5&amp;name=zeniquin-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZENIQUIN 		
					</strong><br><span class="contentTableReg">marbofloxacin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54771-8485</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>marbofloxacin</strong> (marbofloxacin) </td>
<td class="formItem">marbofloxacin</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (Beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">25;MG;PFIZER</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54771-8485-1</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54771-8485-2</td>
<td class="formItem">250  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141151</td>
<td class="formItem">06/26/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZENIQUIN 		
					</strong><br><span class="contentTableReg">marbofloxacin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54771-8488</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>marbofloxacin</strong> (marbofloxacin) </td>
<td class="formItem">marbofloxacin</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (Beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">50;MG;PFIZER</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54771-8488-1</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54771-8488-2</td>
<td class="formItem">250  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141151</td>
<td class="formItem">06/26/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZENIQUIN 		
					</strong><br><span class="contentTableReg">marbofloxacin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54771-8490</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>marbofloxacin</strong> (marbofloxacin) </td>
<td class="formItem">marbofloxacin</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (Beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">100;MG;PFIZER</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54771-8490-1</td>
<td class="formItem">50  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141151</td>
<td class="formItem">06/26/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZENIQUIN 		
					</strong><br><span class="contentTableReg">marbofloxacin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54771-8494</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>marbofloxacin</strong> (marbofloxacin) </td>
<td class="formItem">marbofloxacin</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (Beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">200;MG;PFIZER</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54771-8494-1</td>
<td class="formItem">50  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141151</td>
<td class="formItem">06/26/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Zoetis Inc.
							(828851555)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Zoetis LLC</td>
<td class="formItem"></td>
<td class="formItem">039055157</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Emcure Pharmaceuticals Limited</td>
<td class="formItem"></td>
<td class="formItem">862602830</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">F.I.S. FABBRICA ITALIANA SINTETICI S.P.A.</td>
<td class="formItem"></td>
<td class="formItem">431189117</td>
<td class="formItem">API MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>25f0d2f2-83c0-45e0-9d13-7b351fc0df63</div>
<div>Set id: 05196313-2371-45ad-a6fb-6269f8ef94c5</div>
<div>Version: 1</div>
<div>Effective Time: 20140115</div>
</div>
</div> <div class="DistributorName">Zoetis Inc.</div></p>
</body></html>
